Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms

  • Hong Yan ,

    Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Wuhan University School of Public Health, Wuhan, Hubei, China

  • Xin Chen ,

    Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Program in Molecular Carcinogenesis, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, United States of America

  • Qiuping Zhang ,

    Contributed equally to this work with: Hong Yan, Xin Chen, Qiuping Zhang

    Affiliations Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Department of Immunology, Wuhan University School of Basic Medical Science, Wuhan, Hubei, China

  • Jichao Qin,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Hangwen Li,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Can Liu,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Tammy Calhoun-Davis,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Luis Della Coletta,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Jim Klostergaard,

    Affiliation Department of Molecular and Cellular Oncology, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

  • Izabela Fokt,

    Affiliation Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

  • Stanislaw Skora,

    Affiliation Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

  • Waldemar Priebe,

    Affiliation Department of Experimental Therapeutics, the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States of America

  • Yongyi Bi,

    Affiliation Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America

  • Dean G. Tang

    dtang@mdanderson.org

    Affiliations Department of Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Smithville, Texas, United States of America, Program in Molecular Carcinogenesis, The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, United States of America, Centers for Cancer Epigenetics, Stem Cell and Developmental Biology, RNA Interference and Non-coding RNAs, and Molecular Carcinogenesis, the University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.